Join us for a high-impact Strategic Investor Spotlight with Novo Nordisk, a global healthcare leader with a century-long legacy of scientific innovation and a mission to defeat serious chronic diseases. Novo Nordisk is known for its groundbreaking work in diabetes, obesity, and other chronic conditions – and its strong commitment to collaboration.
Hear from Atul Jain, PhD, Director, Search & Evaluation at Novo Nordisk, as he shares insights into the company’s investment focus, therapeutic areas of interest, and approach to partnering with early-stage innovators. This exclusive event includes a short program and a networking session with refreshments, offering Washington state startups and researchers a unique opportunity to learn more about how to engage with Novo Nordisk.
Novo Nordisk partners with leading scientists, academic and medical institutions, technology startups, biotech innovators and pharmaceutical companies, to turn bold ideas into groundbreaking solutions that are available to patients across the globe. Building on its legacy in diabetes care, the company has expanded into other therapy areas, including obesity, cardiovascular disease and adjacent areas, as well as rare blood and endocrine disorders. If your company is pioneering novel targets, new mechanisms of action and potentially disease-modifying compounds that address unmet medical needs in these indications, don’t miss this chance to connect directly with their partnering teams and explore the potential to team up and pioneer scientific innovation together, to improve the lives of people living with a serious chronic disease.
Agenda:
3:45 Doors open for registration
4:00 Introduction
4:05 Novo Nordisk Company Investment presentation
4:35 Q&A
4:50 Informal networking
If you would like to receive a recording of this event, please email Elizabeth Cross Nichol.